SSA
LXRX icon

Schonfeld Strategic Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Sell
49,435
-25,675
-34% -$50K ﹤0.01% 2281
2026
Q1 		$117K Buy
75,110
+62,002
+473% +$90.2K ﹤0.01% 1857
2025
Q4 		$15.1K Sell
13,108
-812,525
-98% -$1.12M ﹤0.01% 1944
2025
Q3 		$1.11M Sell
825,633
-3,750,519
-82% -$4.26M 0.01% 1309
2025
Q2 		$4.33M Sell
4,576,152
-3,636,841
-44% -$2.36M 0.03% 612
2025
Q1 		$3.78M Buy
8,212,993
+654,372
+9% +$413K 0.02% 637
2024
Q4 		$5.58M Buy
7,558,621
+5,676,021
+301% +$6.84M 0.03% 470
2024
Q3 		$2.96M Buy
1,882,600
+1,311,108
+229% +$2.33M 0.02% 731
2024
Q2 		$3.24M Sell
571,492
-388,658
-40% -$697K 0.02% 699
2024
Q1 		$5.35M Buy
+960,150
New +$2.06M 0.04% 621
2023
Q4 		– Sell
-469,666
Closed -$512K – 2068
2023
Q3 		$512K Sell
469,666
-23,476
-5% -$41.2K ﹤0.01% 1199
2023
Q2 		$1.13M Buy
493,142
+334,142
+210% +$887K 0.01% 934
2023
Q1 		$386K Buy
159,000
+42,000
+36% +$96.2K ﹤0.01% 1273
2022
Q4 		$223K Buy
+117,000
New +$249K ﹤0.01% 1940
2021
Q1 		– Sell
-75,700
Closed -$259K – 2000
2020
Q4 		$259K Buy
+75,700
New +$144K ﹤0.01% 1252
2017
Q4 		– Sell
-15,781
Closed -$194K – 823
2017
Q3 		$194K Buy
+15,781
New +$233K 0.02% 521
2017
Q2 		– Sell
-10,000
Closed -$143K – 699
2017
Q1 		$143K Buy
+10,000
New +$148K 0.01% 559

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Schonfeld Strategic Advisors's LXRX Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Lexicon Pharmaceuticals (LXRX) stake by 34% in Q2 2026, selling an estimated $50K and leaving 49,435 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #2281.

Schonfeld Strategic Advisors first reported a position in LXRX in Q1 2017 and has held it in 17 quarters since. The position peaked at $5.58M in Q4 2024. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Schonfeld Strategic Advisors held 49,435 shares of Lexicon Pharmaceuticals worth $119K as of Q2 2026.
  • Schonfeld Strategic Advisors sold 25,675 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $50K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2281 holding.
  • Schonfeld Strategic Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
  • Schonfeld Strategic Advisors's Lexicon Pharmaceuticals position peaked at $5.58M in Q4 2024.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.